Business
Editas Medicine Announces Fourth Quarter and Full Year 2019 Results and Update
Announcement of first patient dosing with EDIT-101 (AGN-151587) expected in 1Q20 Plan to file IND for EDIT-301 for sickle cell disease by end of 2020 Research
About this update from Editas Medicine, Inc.
[{"type":"text","content":"Announcement of first patient dosing with EDIT-101 (AGN-151587) expected in 1Q20\n Plan to file IND for EDIT-301 for sickle cell disease by end of 2020 Research collaboration with Sandhill Therapeutics accelerates IND-enabling studies for allogeneic healthy donor NK program to treat solid tumors in mid-2020 CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the fourth quarter and full year 2019. “We are entering 2020 with strong momentum and a strategic focus on driving our pipeline of in vivo CRISPR and engineered cell medicines forward with the ultimate vision of developing differentiated, transformational medicines for people living with serious diseases,” said Cynthia Collins, Chief Executive Officer of Editas Medicine. “Our team is making history with the first ever clinical trial of an in vivo CRISPR medicine, advancing our broader pipeline of in vivo CRISPR medicines, and progressing our engineered cell medicines for hemoglobinopathies and cancers. With our recent achievements, I expect our clinical pipeline to yield a robust and sustainable portfolio of differentiated, transformative medicines and ensure the Company’s long-term growth.” Recent Achievements and Outlook In Vivo CRISPR Medicines EDIT-101 (AGN-151587) for LCA10First in vivo CRISPR gene editing trial initiatedEditas Medicine (Company) and its partner, Allergan, are conducting the Brilliance Phase 1/2 clinical trial to evaluate the safety, tolerability, and efficacy of EDIT-101 as a treatment for Leber congenital amaurosis 10 (LCA10). An announcement of first patient dosing is expected in the first quarter of 2020.EDIT-102 for Usher Syndrome 2AReady for IND-enabling studiesEDIT-102 is designed to remove exon 13 of the USH2A gene to restore functional Usherin protein using the same proprietary S. aureus Cas9 enzyme, AAV vector, and tissue-specific promoter as EDIT-101. Under the terms of its alliance agreement with Allergan, the Company has delivered a preclinical data package for EDIT-102 to Allergan for potential licensing and initiation of Investigational New Drug (IND)-enabling studies. Engineered Cell Medicines EDIT-301 for Sickle Cell Disease and Beta-ThalassemiaIND filing for Sickle Cell Disease targeted by end of 2020Edit...